BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Rossi ML, Rehman AA, Gondi CS. Therapeutic options for the management of pancreatic cancer. World J Gastroenterol 2014; 20(32): 11142-11159 [PMID: 25170201 DOI: 10.3748/wjg.v20.i32.11142] [Cited by in CrossRef: 75] [Cited by in F6Publishing: 68] [Article Influence: 9.4] [Reference Citation Analysis]
Number Citing Articles
1 Wang T, Narayanaswamy R, Ren H, Gillespie JW, Petrenko VA, Torchilin VP. Phage-derived protein-mediated targeted chemotherapy of pancreatic cancer. J Drug Target 2018;26:505-15. [PMID: 29132246 DOI: 10.1080/1061186X.2017.1405424] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
2 Kumari S, Sikander M, Malik S, Tripathi MK, Hafeez BB, Yallapu MM, Chauhan SC, Khan S, Jaggi M. Steviol Represses Glucose Metabolism and Translation Initiation in Pancreatic Cancer Cells. Biomedicines 2021;9:1814. [PMID: 34944630 DOI: 10.3390/biomedicines9121814] [Reference Citation Analysis]
3 Park SJ, Kim SM, Moon JH, Kim JH, Shin JS, Hong SW, Shin YJ, Lee DH, Lee EY, Hwang IY, Kim JE, Kim KP, Hong YS, Lee WK, Choi EK, Lee JS, Jin DH, Kim TW. SAHA, an HDAC inhibitor, overcomes erlotinib resistance in human pancreatic cancer cells by modulating E-cadherin. Tumour Biol 2016;37:4323-30. [PMID: 26493999 DOI: 10.1007/s13277-015-4216-2] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
4 Tsai WC, Bai LY, Chen YJ, Chu PC, Hsu YW, Sargeant AM, Weng JR. OSU-A9 inhibits pancreatic cancer cell lines by modulating p38-JAK-STAT3 signaling. Oncotarget 2017;8:29233-46. [PMID: 28418923 DOI: 10.18632/oncotarget.16450] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
5 Gonzalez-Valdivieso J, Garcia-Sampedro A, Hall AR, Girotti A, Arias FJ, Pereira SP, Acedo P. Smart Nanoparticles as Advanced Anti-Akt Kinase Delivery Systems for Pancreatic Cancer Therapy. ACS Appl Mater Interfaces 2021;13:55790-805. [PMID: 34788541 DOI: 10.1021/acsami.1c14592] [Reference Citation Analysis]
6 Uchida S, Kinoh H, Ishii T, Matsui A, Tockary TA, Takeda KM, Uchida H, Osada K, Itaka K, Kataoka K. Systemic delivery of messenger RNA for the treatment of pancreatic cancer using polyplex nanomicelles with a cholesterol moiety. Biomaterials 2016;82:221-8. [PMID: 26763736 DOI: 10.1016/j.biomaterials.2015.12.031] [Cited by in Crossref: 69] [Cited by in F6Publishing: 64] [Article Influence: 9.9] [Reference Citation Analysis]
7 Joshi AD, Catravas JD. Commentary: CHIPping away pancreatic tumors? Ann Transl Med 2014;2:105. [PMID: 25489579 DOI: 10.3978/j.issn.2305-5839.2014.11.01] [Reference Citation Analysis]
8 Zhu JH, Yan QL, Wang JW, Chen Y, Ye QH, Wang ZJ, Huang T. The Key Genes for Perineural Invasion in Pancreatic Ductal Adenocarcinoma Identified With Monte-Carlo Feature Selection Method. Front Genet 2020;11:554502. [PMID: 33193628 DOI: 10.3389/fgene.2020.554502] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Klinghammer K, Walther W, Hoffmann J. Choosing wisely - Preclinical test models in the era of precision medicine. Cancer Treat Rev 2017;55:36-45. [PMID: 28314175 DOI: 10.1016/j.ctrv.2017.02.009] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 4.4] [Reference Citation Analysis]
10 Wang A, Dai H, Gong Y, Zhang C, Shu J, Luo Y, Jiang Y, Liu W, Bie P. ANLN-induced EZH2 upregulation promotes pancreatic cancer progression by mediating miR-218-5p/LASP1 signaling axis. J Exp Clin Cancer Res 2019;38:347. [PMID: 31395079 DOI: 10.1186/s13046-019-1340-7] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 7.3] [Reference Citation Analysis]
11 Olson MT, Ly QP, Mohs AM. Fluorescence Guidance in Surgical Oncology: Challenges, Opportunities, and Translation. Mol Imaging Biol. 2019;21:200-218. [PMID: 29942988 DOI: 10.1007/s11307-018-1239-2] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 6.7] [Reference Citation Analysis]
12 Camelo F, Le A. The Intricate Metabolism of Pancreatic Cancers. Adv Exp Med Biol 2021;1311:77-88. [PMID: 34014535 DOI: 10.1007/978-3-030-65768-0_5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 Pan P, Skaer C, Yu J, Zhao H, Ren H, Oshima K, Wang LS. Berries and other natural products in the pancreatic cancer chemoprevention in human clinical trials. J Berry Res 2017;7:147-61. [PMID: 29367867 DOI: 10.3233/JBR-170159] [Cited by in Crossref: 33] [Cited by in F6Publishing: 13] [Article Influence: 6.6] [Reference Citation Analysis]
14 Duan Y, Yin X, Lai X, Liu C, Nie W, Li D, Xie Z, Li Z, Meng F. Upregulation of DAB2IP Inhibits Ras Activity and Tumorigenesis in Human Pancreatic Cancer Cells. Technol Cancer Res Treat 2020;19:1533033819895494. [PMID: 32336215 DOI: 10.1177/1533033819895494] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
15 Zhong Y, Liu J, Li X, Westin SN, Malpica A, Lawson BC, Lee S, Fellman BM, Coleman RL, Sood AK, Fleming ND. A Modified 2 Tier Chemotherapy Response Score (CRS) and Other Histopathologic Features for Predicting Outcomes of Patients with Advanced Extrauterine High-Grade Serous Carcinoma after Neoadjuvant Chemotherapy. Cancers (Basel) 2021;13:704. [PMID: 33572451 DOI: 10.3390/cancers13040704] [Reference Citation Analysis]
16 Hernandez-Unzueta I, Benedicto A, Romayor I, Herrero A, Sanz E, Arteta B, Olaso E, Márquez J. Ocoxin Oral Solution Exerts an Antitumoral Effect in Pancreatic Cancer and Reduces the Stromal-Mediated Chemoresistance. Pancreas 2019;48:555-67. [PMID: 30946238 DOI: 10.1097/MPA.0000000000001277] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
17 Gnanamony M, Gondi CS. Chemoresistance in pancreatic cancer: Emerging concepts. Oncol Lett. 2017;13:2507-2513. [PMID: 28454427 DOI: 10.3892/ol.2017.5777] [Cited by in Crossref: 34] [Cited by in F6Publishing: 30] [Article Influence: 6.8] [Reference Citation Analysis]
18 Kim SH, Woo YS, Lee KH, Lee JK, Lee KT, Park JK, Kang SH, Kim JW, Park JK, Park S. Preoperative EUS-guided FNA: effects on peritoneal recurrence and survival in patients with pancreatic cancer. Gastrointestinal Endoscopy 2018;88:926-34. [DOI: 10.1016/j.gie.2018.06.024] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 3.8] [Reference Citation Analysis]
19 Leca J, Martinez S, Lac S, Nigri J, Secq V, Rubis M, Bressy C, Sergé A, Lavaut MN, Dusetti N, Loncle C, Roques J, Pietrasz D, Bousquet C, Garcia S, Granjeaud S, Ouaissi M, Bachet JB, Brun C, Iovanna JL, Zimmermann P, Vasseur S, Tomasini R. Cancer-associated fibroblast-derived annexin A6+ extracellular vesicles support pancreatic cancer aggressiveness. J Clin Invest 2016;126:4140-56. [PMID: 27701147 DOI: 10.1172/JCI87734] [Cited by in Crossref: 107] [Cited by in F6Publishing: 75] [Article Influence: 17.8] [Reference Citation Analysis]
20 Li X, Li J, Zhang B, Gu Y, Li Q, Gu G, Xiong J, Li Y, Yang X, Qian Z. Comparative peptidome profiling reveals critical roles for peptides in the pathology of pancreatic cancer. Int J Biochem Cell Biol 2020;120:105687. [PMID: 31927104 DOI: 10.1016/j.biocel.2020.105687] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
21 Yu Z, Zhao S, Wang L, Wang J, Zhou J. miRNA-339-5p Plays an Important Role in Invasion and Migration of Pancreatic Cancer Cells. Med Sci Monit 2019;25:7509-17. [PMID: 31588120 DOI: 10.12659/MSM.917038] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
22 Goldsmith C, Price P, Cross T, Loughlin S, Cowley I, Plowman N. Dose-Volume Histogram Analysis of Stereotactic Body Radiotherapy Treatment of Pancreatic Cancer: A Focus on Duodenal Dose Constraints. Seminars in Radiation Oncology 2016;26:149-56. [DOI: 10.1016/j.semradonc.2015.12.002] [Cited by in Crossref: 22] [Cited by in F6Publishing: 17] [Article Influence: 3.7] [Reference Citation Analysis]
23 Fontana G, Riboldi M, Gianoli C, Chirvase CI, Villa G, Paganelli C, Summers PE, Tagaste B, Pella A, Fossati P, Ciocca M, Baroni G, Valvo F, Orecchia R. MRI quantification of pancreas motion as a function of patient setup for particle therapy -a preliminary study. J Appl Clin Med Phys 2016;17:60-75. [PMID: 27685119 DOI: 10.1120/jacmp.v17i5.6236] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.3] [Reference Citation Analysis]
24 Li M, Xu H. Fear stress enhanced xenograft pancreatic tumor growth through activating epithelial-mesenchymal transition. Pancreatology 2019;19:377-82. [PMID: 30733163 DOI: 10.1016/j.pan.2019.01.002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
25 Wang L, Luo J, Li Y, Lu Y, Zhang Y, Tian B, Zhao Z, Hu Q. Mitochondrial-Associated Protein LRPPRC is Related With Poor Prognosis Potentially and Exerts as an Oncogene Via Maintaining Mitochondrial Function in Pancreatic Cancer. Front Genet 2022;12:817672. [DOI: 10.3389/fgene.2021.817672] [Reference Citation Analysis]
26 García-Reyes B, Kretz AL, Ruff JP, von Karstedt S, Hillenbrand A, Knippschild U, Henne-Bruns D, Lemke J. The Emerging Role of Cyclin-Dependent Kinases (CDKs) in Pancreatic Ductal Adenocarcinoma. Int J Mol Sci 2018;19:E3219. [PMID: 30340359 DOI: 10.3390/ijms19103219] [Cited by in Crossref: 20] [Cited by in F6Publishing: 24] [Article Influence: 5.0] [Reference Citation Analysis]
27 Wang S, Bager CL, Karsdal MA, Chondros D, Taverna D, Willumsen N. Blood-based extracellular matrix biomarkers as predictors of survival in patients with metastatic pancreatic ductal adenocarcinoma receiving pegvorhyaluronidase alfa. J Transl Med 2021;19:39. [PMID: 33478521 DOI: 10.1186/s12967-021-02701-z] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
28 Xing H, Hao Z, Zhu W, Sun D, Ding J, Zhang H, Liu Y, Huo L. Preoperative prediction of pathological grade in pancreatic ductal adenocarcinoma based on 18F-FDG PET/CT radiomics. EJNMMI Res. 2021;11:19. [PMID: 33630176 DOI: 10.1186/s13550-021-00760-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
29 de Souza PC, Ranjan A, Towner RA. Nanoformulations for therapy of pancreatic and liver cancers. Nanomedicine 2015;10:1515-34. [DOI: 10.2217/nnm.14.231] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
30 Kosmidis C, Sapalidis K, Kotidis E, Mixalopoulos N, Zarogoulidis P, Tsavlis D, Baka S, Man YG, Kanellos J. Pancreatic cancer from bench to bedside: molecular pathways and treatment options. Ann Transl Med 2016;4:165. [PMID: 27275478 DOI: 10.21037/atm.2016.05.11] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
31 Tang B, Li Y, Qi G, Yuan S, Wang Z, Yu S, Li B, He S. Clinicopathological Significance of CDKN2A Promoter Hypermethylation Frequency with Pancreatic Cancer. Sci Rep 2015;5:13563. [PMID: 26338139 DOI: 10.1038/srep13563] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 4.0] [Reference Citation Analysis]
32 Gupta SD, Swapanthi PS, Bhagya D, Federicci F, Mazaira GI, Galigniana MD, Subrahmanyam CVS, Gowrishankar NL, Raghavendra NM. Rational Identification of Hsp90 Inhibitors as Anticancer Lead Molecules by Structure Based Drug Designing Approach. Anticancer Agents Med Chem 2020;20:369-85. [PMID: 31713499 DOI: 10.2174/1871520619666191111152050] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
33 Alhakamy NA, Ahmed OAA, Fahmy UA, Md S. Apamin-Conjugated Alendronate Sodium Nanocomplex for Management of Pancreatic Cancer. Pharmaceuticals (Basel) 2021;14:729. [PMID: 34451826 DOI: 10.3390/ph14080729] [Reference Citation Analysis]
34 Zhang Z, Che X, Yang N, Bai Z, Wu Y, Zhao L, Pei H. miR-135b-5p Promotes migration, invasion and EMT of pancreatic cancer cells by targeting NR3C2. Biomed Pharmacother 2017;96:1341-8. [PMID: 29196101 DOI: 10.1016/j.biopha.2017.11.074] [Cited by in Crossref: 37] [Cited by in F6Publishing: 36] [Article Influence: 7.4] [Reference Citation Analysis]
35 Larentzakis A, Anagnostou E, Georgiou K, Vrakopoulou GZ, Zografos CG, Zografos GC, Toutouzas KG. Place of hyperthermic intraperitoneal chemotherapy in the armament against pancreatic adenocarcinoma: A survival, mortality and morbidity systematic review. Oncol Lett 2021;21:246. [PMID: 33664810 DOI: 10.3892/ol.2021.12507] [Reference Citation Analysis]
36 Zhang J, Xu X, Shi M, Chen Y, Yu D, Zhao C, Gu Y, Yang B, Guo S, Ding G, Jin G, Wu CL, Zhu M. CD13hi Neutrophil-like myeloid-derived suppressor cells exert immune suppression through Arginase 1 expression in pancreatic ductal adenocarcinoma. Oncoimmunology 2017;6:e1258504. [PMID: 28344866 DOI: 10.1080/2162402X.2016.1258504] [Cited by in Crossref: 27] [Cited by in F6Publishing: 21] [Article Influence: 5.4] [Reference Citation Analysis]
37 Li JR, Liu L, Luo H, Chen ZG, Wang JH, Li NF. Long Noncoding RNA DUXAP8 Promotes Pancreatic Carcinoma Cell Migration and Invasion Via Pathway by miR-448/WTAP/Fak Signaling Axis. Pancreas 2021;50:317-26. [PMID: 33625109 DOI: 10.1097/MPA.0000000000001751] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
38 Dhar D, Raina K, Kumar D, Wempe MF, Bagby SM, Pitts TM, Orlicky DJ, Agarwal C, Messersmith WA, Agarwal R. Bitter melon juice intake with gemcitabine intervention circumvents resistance to gemcitabine in pancreatic patient-derived xenograft tumors. Mol Carcinog 2020;59:1227-40. [PMID: 32816368 DOI: 10.1002/mc.23251] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
39 He L, Niu L, Korpan NN, Sumida S, Xiao Y, Li J, Sutedja B, Lu Y, Zuo J, Liu J, Xu K. Clinical Practice Guidelines for Cryosurgery of Pancreatic Cancer: A Consensus Statement From the China Cooperative Group of Cryosurgery on Pancreatic Cancer, International Society of Cryosurgery, and Asian Society of Cryosurgery. Pancreas 2017;46:967-72. [PMID: 28742542 DOI: 10.1097/MPA.0000000000000878] [Cited by in Crossref: 7] [Cited by in F6Publishing: 1] [Article Influence: 1.8] [Reference Citation Analysis]
40 Lu S, Ahmed T, Du P, Wang Y. Genomic Variations in Pancreatic Cancer and Potential Opportunities for Development of New Approaches for Diagnosis and Treatment. Int J Mol Sci 2017;18:E1201. [PMID: 28587243 DOI: 10.3390/ijms18061201] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
41 Luo XM, Niu LZ, Chen JB, Xu KC. Advances in cryoablation for pancreatic cancer. World J Gastroenterol 2016; 22(2): 790-800 [PMID: 26811625 DOI: 10.3748/wjg.v22.i2.790] [Cited by in CrossRef: 16] [Cited by in F6Publishing: 11] [Article Influence: 2.7] [Reference Citation Analysis]
42 Hingorani SR, Zheng L, Bullock AJ, Seery TE, Harris WP, Sigal DS, Braiteh F, Ritch PS, Zalupski MM, Bahary N, Oberstein PE, Wang-Gillam A, Wu W, Chondros D, Jiang P, Khelifa S, Pu J, Aldrich C, Hendifar AE. HALO 202: Randomized Phase II Study of PEGPH20 Plus Nab-Paclitaxel/Gemcitabine Versus Nab-Paclitaxel/Gemcitabine in Patients With Untreated, Metastatic Pancreatic Ductal Adenocarcinoma. J Clin Oncol. 2018;36:359-366. [PMID: 29232172 DOI: 10.1200/jco.2017.74.9564] [Cited by in Crossref: 195] [Cited by in F6Publishing: 135] [Article Influence: 39.0] [Reference Citation Analysis]
43 Karanikas M, Esempidis A, Chasan ZT, Deftereou T, Antonopoulou M, Bozali F, Amarantidis K, Man YG. Pancreatic Cancer from Molecular Pathways to Treatment Opinion. J Cancer 2016;7:1328-39. [PMID: 27390608 DOI: 10.7150/jca.15419] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 2.2] [Reference Citation Analysis]
44 Duan Q, Li H, Gao C, Zhao H, Wu S, Wu H, Wang C, Shen Q, Yin T. High glucose promotes pancreatic cancer cells to escape from immune surveillance via AMPK-Bmi1-GATA2-MICA/B pathway. J Exp Clin Cancer Res. 2019;38:192. [PMID: 31088566 DOI: 10.1186/s13046-019-1209-9] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
45 Wan J, Cui J, Wang L, Wu K, Hong X, Zou Y, Zhao S, Ke H. Excessive mitochondrial fragmentation triggered by erlotinib promotes pancreatic cancer PANC-1 cell apoptosis via activating the mROS-HtrA2/Omi pathways. Cancer Cell Int 2018;18:165. [PMID: 30377412 DOI: 10.1186/s12935-018-0665-1] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.5] [Reference Citation Analysis]
46 Ibrahim AM, Wang YH. Viro-immune therapy: A new strategy for treatment of pancreatic cancer. World J Gastroenterol 2016; 22(2): 748-763 [PMID: 26811622 DOI: 10.3748/wjg.v22.i2.748] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
47 Chini CC, Espindola-Netto JM, Mondal G, Guerrico AM, Nin V, Escande C, Sola-Penna M, Zhang JS, Billadeau DD, Chini EN. SIRT1-Activating Compounds (STAC) Negatively Regulate Pancreatic Cancer Cell Growth and Viability Through a SIRT1 Lysosomal-Dependent Pathway. Clin Cancer Res 2016;22:2496-507. [PMID: 26655844 DOI: 10.1158/1078-0432.CCR-15-1760] [Cited by in Crossref: 21] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
48 Zhang H, Zhang X, Li X, Meng WB, Bai ZT, Rui SZ, Wang ZF, Zhou WC, Jin XD. Effect of CCNB1 silencing on cell cycle, senescence, and apoptosis through the p53 signaling pathway in pancreatic cancer. J Cell Physiol. 2018;234:619-631. [PMID: 30069972 DOI: 10.1002/jcp.26816] [Cited by in Crossref: 28] [Cited by in F6Publishing: 38] [Article Influence: 7.0] [Reference Citation Analysis]
49 Rudno-Rudzińska J, Kielan W, Guziński M, Płochocki M, Antończyk A, Kulbacka J. New therapeutic strategy: Personalization of pancreatic cancer treatment-irreversible electroporation (IRE), electrochemotherapy (ECT) and calcium electroporation (CaEP) - A pilot preclinical study. Surg Oncol 2021;38:101634. [PMID: 34303953 DOI: 10.1016/j.suronc.2021.101634] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
50 Zhou Y, Shan T, Ding W, Hua Z, Shen Y, Lu Z, Chen B, Dai T. Study on mechanism about long noncoding RNA MALAT1 affecting pancreatic cancer by regulating Hippo-YAP signaling. J Cell Physiol 2018;233:5805-14. [PMID: 29215734 DOI: 10.1002/jcp.26357] [Cited by in Crossref: 31] [Cited by in F6Publishing: 32] [Article Influence: 7.8] [Reference Citation Analysis]
51 Chen Q, Wang WJ, Jia YX, Yuan H, Wu PF, Ge WL, Meng LD, Huang XM, Shen P, Yang TY, Miao Y, Zhang JJ, Jiang KR. Effect of the transcription factor YY1 on the development of pancreatic endocrine and exocrine tumors: a narrative review. Cell Biosci 2021;11:86. [PMID: 33985581 DOI: 10.1186/s13578-021-00602-8] [Reference Citation Analysis]
52 Camelo F, Le A. The Intricate Metabolism of Pancreatic Cancers. In: Le A, editor. The Heterogeneity of Cancer Metabolism. Cham: Springer International Publishing; 2018. pp. 73-81. [DOI: 10.1007/978-3-319-77736-8_5] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
53 Benzel J, Fendrich V. Familial Pancreatic Cancer. Oncol Res Treat. 2018;41:611-618. [PMID: 30269130 DOI: 10.1159/000493473] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 3.5] [Reference Citation Analysis]
54 Wang Z, Shen W, Li X, Feng Y, Qian K, Wang G, Gao Y, Xu X, Zhang S, Yue L, Cao J. The PPARγ Agonist Rosiglitazone Enhances the Radiosensitivity of Human Pancreatic Cancer Cells. Drug Des Devel Ther 2020;14:3099-110. [PMID: 32801648 DOI: 10.2147/DDDT.S242557] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
55 Wu J, Li Z, Li Y, Pettitt A, Zhou F. Photothermal Effects of Reduced Graphene Oxide on Pancreatic Cancer. Technol Cancer Res Treat 2018;17:1533034618768637. [PMID: 29665743 DOI: 10.1177/1533034618768637] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 4.7] [Reference Citation Analysis]
56 Spano C, Grisendi G, Golinelli G, Rossignoli F, Prapa M, Bestagno M, Candini O, Petrachi T, Recchia A, Miselli F, Rovesti G, Orsi G, Maiorana A, Manni P, Veronesi E, Piccinno MS, Murgia A, Pinelli M, Horwitz EM, Cascinu S, Conte P, Dominici M. Soluble TRAIL Armed Human MSC As Gene Therapy For Pancreatic Cancer. Sci Rep 2019;9:1788. [PMID: 30742129 DOI: 10.1038/s41598-018-37433-6] [Cited by in Crossref: 32] [Cited by in F6Publishing: 33] [Article Influence: 10.7] [Reference Citation Analysis]
57 Behrens D, Walther W, Fichtner I. Pancreatic cancer models for translational research. Pharmacol Ther 2017;173:146-58. [PMID: 28174092 DOI: 10.1016/j.pharmthera.2017.02.013] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 3.8] [Reference Citation Analysis]
58 Espindola-Netto JM, Chini CCS, Tarragó M, Wang E, Dutta S, Pal K, Mukhopadhyay D, Sola-Penna M, Chini EN. Preclinical efficacy of the novel competitive NAMPT inhibitor STF-118804 in pancreatic cancer. Oncotarget 2017;8:85054-67. [PMID: 29156703 DOI: 10.18632/oncotarget.18841] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 3.8] [Reference Citation Analysis]
59 Liu YF, Luo D, Li X, Li ZQ, Yu X, Zhu HW. PVT1 Knockdown Inhibits Autophagy and Improves Gemcitabine Sensitivity by Regulating the MiR-143/HIF-1α/VMP1 Axis in Pancreatic Cancer. Pancreas 2021;50:227-34. [PMID: 33565800 DOI: 10.1097/MPA.0000000000001747] [Reference Citation Analysis]
60 Ashida R, Nakamura M, Yoshimura M, Mizowaki T. Impact of interfractional anatomical variation and setup correction methods on interfractional dose variation in IMPT and VMAT plans for pancreatic cancer patients: A planning study. J Appl Clin Med Phys 2020;21:49-59. [PMID: 32350969 DOI: 10.1002/acm2.12883] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
61 Hu D, Chen Z, Sheng Z, Gao D, Yan F, Ma T, Zheng H, Hong M. A catalase-loaded hierarchical zeolite as an implantable nanocapsule for ultrasound-guided oxygen self-sufficient photodynamic therapy against pancreatic cancer. Nanoscale 2018;10:17283-92. [PMID: 30198041 DOI: 10.1039/c8nr05548c] [Cited by in Crossref: 34] [Cited by in F6Publishing: 15] [Article Influence: 11.3] [Reference Citation Analysis]
62 Gao CT, Ren J, Yu J, Li SN, Guo XF, Zhou YZ. KIF23 enhances cell proliferation in pancreatic ductal adenocarcinoma and is a potent therapeutic target. Ann Transl Med 2020;8:1394. [PMID: 33313139 DOI: 10.21037/atm-20-1970] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
63 Mitra S, Ganguli S, Chakrabarti J. Introduction. Cancer and Noncoding RNAs. Elsevier; 2018. pp. 1-23. [DOI: 10.1016/b978-0-12-811022-5.00001-2] [Cited by in Crossref: 2] [Article Influence: 0.5] [Reference Citation Analysis]
64 Liu Q, Li Y, Yao L. Knockdown of AGR2 induces cell apoptosis and reduces chemotherapy resistance of pancreatic cancer cells with the involvement of ERK/AKT axis. Pancreatology 2018;18:678-88. [DOI: 10.1016/j.pan.2018.07.003] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
65 Behrens D, Rolff J, Hoffmann J. Predictive In Vivo Models for Oncology. Handb Exp Pharmacol 2016;232:203-21. [PMID: 26489829 DOI: 10.1007/164_2015_29] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
66 Zhang Y, Zhang XX, Yuan RY, Ren T, Shao ZY, Wang HF, Cai WL, Chen LT, Wang XA, Wang P. Cordycepin induces apoptosis in human pancreatic cancer cells via the mitochondrial-mediated intrinsic pathway and suppresses tumor growth in vivo. Onco Targets Ther 2018;11:4479-90. [PMID: 30122940 DOI: 10.2147/OTT.S164670] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 2.8] [Reference Citation Analysis]
67 Yu Y, Dong JT, He B, Zou YF, Li XS, Xi CH, Yu Y. LncRNA SNHG16 induces the SREBP2 to promote lipogenesis and enhance the progression of pancreatic cancer. Future Oncol 2019;15:3831-44. [PMID: 31664866 DOI: 10.2217/fon-2019-0321] [Cited by in Crossref: 14] [Cited by in F6Publishing: 18] [Article Influence: 4.7] [Reference Citation Analysis]
68 Rao X, Wan L, Jie Z, Zhu X, Yin J, Cao H. Upregulated miR-27a-3p Indicates a Poor Prognosis in Pancreatic Carcinoma Patients and Promotes the Angiogenesis and Migration by Epigenetic Silencing of GATA6 and Activating VEGFA/VEGFR2 Signaling Pathway. Onco Targets Ther 2019;12:11241-54. [PMID: 31908490 DOI: 10.2147/OTT.S220621] [Cited by in Crossref: 15] [Cited by in F6Publishing: 7] [Article Influence: 5.0] [Reference Citation Analysis]
69 Kladi-Skandali A, Michaelidou K, Scorilas A, Mavridis K. Long Noncoding RNAs in Digestive System Malignancies: A Novel Class of Cancer Biomarkers and Therapeutic Targets? Gastroenterol Res Pract 2015;2015:319861. [PMID: 26064090 DOI: 10.1155/2015/319861] [Cited by in Crossref: 13] [Cited by in F6Publishing: 20] [Article Influence: 1.9] [Reference Citation Analysis]
70 Hevert EAC, Howser CG, Gould ML, Brown DB. Ablative, Endovascular, and Biliary Interventions for Patients with Pancreatic Cancer. Semin Intervent Radiol 2019;36:203-12. [PMID: 31435128 DOI: 10.1055/s-0039-1693118] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
71 Mandili G, Curcio C, Bulfamante S, Follia L, Ferrero G, Mazza E, Principe M, Cordero F, Satolli MA, Spadi R, Evangelista A, Giordano D, Viet D, Cappello P, Novelli F. In pancreatic cancer, chemotherapy increases antitumor responses to tumor-associated antigens and potentiates DNA vaccination. J Immunother Cancer 2020;8:e001071. [PMID: 33115943 DOI: 10.1136/jitc-2020-001071] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
72 Kamimura K, Yokoo T, Terai S. Gene Therapy for Pancreatic Diseases: Current Status. Int J Mol Sci. 2018;19. [PMID: 30384450 DOI: 10.3390/ijms19113415] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]